Neuronal signaling最新文献

{"title":"MEF2C and HDAC5 regulate <i>Egr1</i> and <i>Arc</i> genes to increase dendritic spine density and complexity in early enriched environment.","authors":"Shu Juan Puang,&nbsp;Bavani Elanggovan,&nbsp;Tendy Ching,&nbsp;Judy C G Sng","doi":"10.1042/NS20190147","DOIUrl":"https://doi.org/10.1042/NS20190147","url":null,"abstract":"<p><p>We investigated the effects of environmental enrichment during critical period of early postnatal life and how it interplays with the epigenome to affect experience-dependent visual cortical plasticity. Mice raised in an EE from birth to during CP have increased spine density and dendritic complexity in the visual cortex. EE upregulates synaptic plasticity genes, <i>Arc</i> and <i>Egr1</i>, and a transcription factor MEF2C. We also observed an increase in MEF2C binding to the promoters of <i>Arc</i> and <i>Egr1</i>. In addition, pups raised in EE show a reduction in HDAC5 and its binding to promoters of <i>Mef2c, Arc</i> and <i>Egr1</i> genes. With an overexpression of <i>Mef2c</i>, neurite outgrowth increased in complexity. Our results suggest a possible underlying molecular mechanism of EE, acting through MEF2C and HDAC5, which drive <i>Arc</i> and <i>Egr1.</i> This could lead to the observed increased dendritic spine density and complexity induced by early EE.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 3","pages":"NS20190147"},"PeriodicalIF":0.0,"publicationDate":"2020-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378308/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38194736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The class II histone deacetylases as therapeutic targets for Parkinson's disease.","authors":"Martina Mazzocchi,&nbsp;Louise M Collins,&nbsp;Aideen M Sullivan,&nbsp;Gerard W O'Keeffe","doi":"10.1042/NS20200001","DOIUrl":"https://doi.org/10.1042/NS20200001","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by specific motor impairments. The neuropathological hallmarks of PD include progressive degeneration of midbrain dopaminergic neurons, and loss of their axonal projections to the striatum. Additionally, there is progressive accumulation and spread of intracellular aggregates of α-synuclein. Although dopamine-replacement pharmacotherapy can treat PD symptoms in the short-term, there is a critical need for the development of disease-modifying therapies based on an understanding of the underlying disease mechanisms. One such mechanism is histone acetylation, which is a common epigenetic modification that alters gene transcription. A number of studies have described alterations in histone acetylation in the brains of PD patients. Moreover, α-synuclein accumulation has been linked to alterations in histone acetylation and pharmacological strategies aimed at modulating histone acetylation are under investigation as novel approaches to disease modification in PD. Currently, such strategies are focused predominantly on pan-inhibition of histone deacetylase (HDAC) enzymes. Inhibition of specific individual HDAC enzymes is a more targeted strategy that may allow for future clinical translation. However, the most appropriate class of HDACs that should be targeted for neuroprotection in PD is still unclear. Recent work has shed new light on the role of class-II HDACs in dopaminergic degeneration. For this reason, here we describe the regulation of histone acetylation, outline the evidence for alterations in histone acetylation in the PD brain, and focus on the roles of class II HDACs and the potential of class-II HDAC inhibition as a therapeutic approach for neuroprotection in PD.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 2","pages":"NS20200001"},"PeriodicalIF":0.0,"publicationDate":"2020-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38194734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanisms and roles of mitochondrial localisation and dynamics in neuronal function.","authors":"Richard Seager,&nbsp;Laura Lee,&nbsp;Jeremy M Henley,&nbsp;Kevin A Wilkinson","doi":"10.1042/NS20200008","DOIUrl":"https://doi.org/10.1042/NS20200008","url":null,"abstract":"<p><p>Neurons are highly polarised, complex and incredibly energy intensive cells, and their demand for ATP during neuronal transmission is primarily met by oxidative phosphorylation by mitochondria. Thus, maintaining the health and efficient function of mitochondria is vital for neuronal integrity, viability and synaptic activity. Mitochondria do not exist in isolation, but constantly undergo cycles of fusion and fission, and are actively transported around the neuron to sites of high energy demand. Intriguingly, axonal and dendritic mitochondria exhibit different morphologies. In axons mitochondria are small and sparse whereas in dendrites they are larger and more densely packed. The transport mechanisms and mitochondrial dynamics that underlie these differences, and their functional implications, have been the focus of concerted investigation. Moreover, it is now clear that deficiencies in mitochondrial dynamics can be a primary factor in many neurodegenerative diseases. Here, we review the role that mitochondrial dynamics play in neuronal function, how these processes support synaptic transmission and how mitochondrial dysfunction is implicated in neurodegenerative disease.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 2","pages":"NS20200008"},"PeriodicalIF":0.0,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38194737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A role for TGFβ signalling in medium spiny neuron differentiation of human pluripotent stem cells.","authors":"Marija Fjodorova,&nbsp;Zoe Noakes,&nbsp;Meng Li","doi":"10.1042/NS20200004","DOIUrl":"https://doi.org/10.1042/NS20200004","url":null,"abstract":"<p><p>Activin A and other TGFβ family members have been shown to exhibit a certain degree of promiscuity between their family of receptors. We previously developed an efficient differentiation protocol using Activin A to obtain medium spiny neurons (MSNs) from human pluripotent stem cells (hPSCs). However, the mechanism underlying Activin A-induced MSN fate specification remains largely unknown. Here we begin to tease apart the different components of TGFβ pathways involved in MSN differentiation and demonstrate that Activin A acts exclusively via ALK4/5 receptors to induce MSN progenitor fate during differentiation. Moreover, we show that Alantolactone, an indirect activator of SMAD2/3 signalling, offers an alternative approach to differentiate hPSC-derived forebrain progenitors into MSNs. Further fine tuning of TGFβ pathway by inhibiting BMP signalling with LDN193189 achieves accelerated MSN fate specification. The present study therefore establishes an essential role for TGFβ signalling in human MSN differentiation and provides a fully defined and highly adaptable small molecule-based protocol to obtain MSNs from hPSCs.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 2","pages":"NS20200004"},"PeriodicalIF":0.0,"publicationDate":"2020-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38194735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of distinct type 1 bone morphogenetic protein receptors with different molecular pathways and survival outcomes in neuroblastoma.","authors":"Amnah M Alshangiti,&nbsp;Sean L Wyatt,&nbsp;Erin McCarthy,&nbsp;Louise M Collins,&nbsp;Shane V Hegarty,&nbsp;Aideen M Sullivan,&nbsp;Gerard W O'Keeffe","doi":"10.1042/NS20200006","DOIUrl":"https://doi.org/10.1042/NS20200006","url":null,"abstract":"<p><p>Neuroblastoma (NB) is a paediatric cancer that arises in the sympathetic nervous system. Patients with stage 4 tumours have poor outcomes and 20% of high-risk cases have <i>MYCN</i> amplification. The bone morphogenetic proteins (BMPs) play roles in sympathetic neuritogenesis, by signalling through bone morphogenetic protein receptor (BMPR)2 and either BMPR1A or BMPR1B. Alterations in BMPR2 expression have been reported in NB; it is unknown if the expression of BMPR1A or BMPR1B is altered. We report lower <i>BMPR2</i> and <i>BMPR1B</i>, and higher <i>BMPR1A</i>, expression in stage 4 and in <i>MYCN</i>-amplified NB. Kaplan-Meier plots showed that high <i>BMPR2</i> or <i>BMPR1B</i> expression was linked to better survival, while high <i>BMPR1A</i> was linked to worse survival. Gene ontology enrichment and pathway analyses revealed that <i>BMPR2</i> and <i>BMPR1B</i> co-expressed genes were enriched in those associated with NB differentiation. <i>BMPR1A</i> co-expressed genes were enriched in those associated with cell proliferation. Moreover, the correlation between <i>BMPR2</i> and <i>BMPR1A</i> was strengthened, while the correlation between <i>BMPR2</i> and <i>BMPR1B</i> was lost, in <i>MYCN</i>-amplified NB. This suggested that differentiation should decrease <i>BMPR1A</i> and increase <i>BMPR1B</i> expression. In agreement, nerve growth factor treatment of cultured sympathetic neurons decreased <i>Bmpr1a</i> expression and increased <i>Bmpr1b</i> expression. Overexpression of dominant negative BMPR1B, treatment with a BMPR1B inhibitor and treatment with GDF5, which signals via BMPR1B, showed that BMPR1B signalling is required for optimal neuritogenesis in NB cells, suggesting that loss of <i>BMPR1B</i> may alter neuritogenesis. The present study shows that expression of distinct BMPRs is associated with different survival outcomes in NB.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 1","pages":"NS20200006"},"PeriodicalIF":0.0,"publicationDate":"2020-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38194733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cortical cells are altered by factors including bone morphogenetic protein released from a placental barrier model under altered oxygenation.","authors":"Veronica H L Leinster, Thomas J Phillips, Nicola Jones, Sharon Sanderson, Katja Simon, Jon Hanley, Charles Patrick Case","doi":"10.1042/NS20190148","DOIUrl":"10.1042/NS20190148","url":null,"abstract":"<p><p>Episodes of hypoxia and hypoxia/reoxygenation during foetal development have been associated with increased risk of neurodevelopmental conditions presenting in later life. The mechanism for this is not understood; however, several authors have suggested that the placenta plays an important role. Previously we found both placentas from a maternal hypoxia model and pre-eclamptic placentas from patients release factors lead to a loss of dendrite complexity in rodent neurons. Here to further explore the nature and origin of these secretions we exposed a simple <i>in vitro</i> model of the placental barrier, consisting of a barrier of human cytotrophoblasts, to hypoxia or hypoxia/reoxygenation. We then exposed cortical cultures from embryonic rat brains to the conditioned media (CM) from below these exposed barriers and examined changes in cell morphology, number, and receptor presentation. The barriers released factors that reduced dendrite and astrocyte process lengths, decreased GABAB1 staining, and increased astrocyte number. The changes in astrocytes required the presence of neurons and were prevented by inhibition of the SMAD pathway and by neutralising Bone Morphogenetic Proteins (BMPs) 2/4. Barriers exposed to hypoxia/reoxygenation also released factors that reduced dendrite lengths but increased GABAB1 staining. Both oxygen changes caused barriers to release factors that decreased GluN1, GABAAα1 staining and increased GluN3a staining. We find that hypoxia in particular will elicit the release of factors that increase astrocyte number and decrease process length as well as causing changes in the intensity of glutamate and GABA receptor staining. There is some evidence that BMPs are released and contribute to these changes.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 1","pages":"NS20190148"},"PeriodicalIF":0.0,"publicationDate":"2020-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7363303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38194732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-coding RNAs in neuropathic pain.","authors":"Theodora Kalpachidou, Kai K Kummer, Michaela Kress","doi":"10.1042/NS20190099","DOIUrl":"10.1042/NS20190099","url":null,"abstract":"<p><p>Neuro-immune alterations in the peripheral and central nervous system play a role in the pathophysiology of chronic pain in general, and members of the non-coding RNA (ncRNA) family, specifically the short, 22 nucleotide microRNAs (miRNAs) and the long non-coding RNAs (lncRNAs) act as master switches orchestrating both immune as well as neuronal processes. Several chronic disorders reveal unique ncRNA expression signatures, which recently generated big hopes for new perspectives for the development of diagnostic applications. lncRNAs may offer perspectives as candidates indicative of neuropathic pain in liquid biopsies. Numerous studies have provided novel mechanistic insight into the role of miRNAs in the molecular sequelae involved in the pathogenesis of neuropathic pain along the entire pain pathway. Specific processes within neurons, immune cells, and glia as the cellular components of the neuropathic pain triad and the communication paths between them are controlled by specific miRNAs. Therefore, nucleotide sequences mimicking or antagonizing miRNA actions can provide novel therapeutic strategies for pain treatment, provided their human homologues serve the same or similar functions. Increasing evidence also sheds light on the function of lncRNAs, which converge so far mainly on purinergic signalling pathways both in neurons and glia, and possibly even other ncRNA species that have not been explored so far.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"4 1","pages":"NS20190099"},"PeriodicalIF":0.0,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38087015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidized cholesterol species as signaling molecules in the brain: diabetes and Alzheimer's disease.","authors":"Thaddeus K Weigel,&nbsp;Joshua A Kulas,&nbsp;Heather A Ferris","doi":"10.1042/NS20190068","DOIUrl":"https://doi.org/10.1042/NS20190068","url":null,"abstract":"<p><p>Type 2 diabetes is associated with adverse central nervous system effects, including a doubled risk for Alzheimer's disease (AD) and increased risk of cognitive impairment, but the mechanisms connecting diabetes to cognitive decline and dementia are unknown. One possible link between these diseases may be the associated alterations to cholesterol oxidation and metabolism in the brain. We will survey evidence demonstrating alterations to oxysterols in the brain in AD and diabetes and how these oxysterols could contribute to pathology, as well as identifying research questions that have not yet been addressed to allow for a fuller understanding of the role of oxysterols in AD and diabetes.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"3 4","pages":"NS20190068"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37816264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"aPKC in neuronal differentiation, maturation and function.","authors":"Sophie M Hapak,&nbsp;Carla V Rothlin,&nbsp;Sourav Ghosh","doi":"10.1042/NS20190019","DOIUrl":"https://doi.org/10.1042/NS20190019","url":null,"abstract":"<p><p>The atypical Protein Kinase Cs (aPKCs)-PRKCI, PRKCZ and PKMζ-form a subfamily within the Protein Kinase C (PKC) family. These kinases are expressed in the nervous system, including during its development and in adulthood. One of the aPKCs, PKMζ, appears to be restricted to the nervous system. aPKCs are known to play a role in a variety of cellular responses such as proliferation, differentiation, polarity, migration, survival and key metabolic functions such as glucose uptake, that are critical for nervous system development and function. Therefore, these kinases have garnered a lot of interest in terms of their functional role in the nervous system. Here we review the expression and function of aPKCs in neural development and in neuronal maturation and function. Despite seemingly paradoxical findings with genetic deletion <i>versus</i> gene silencing approaches, we posit that aPKCs are likely candidates for regulating many important neurodevelopmental and neuronal functions, and may be associated with a number of human neuropsychiatric diseases.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"3 3","pages":"NS20190019"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37816263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy in the mammalian nervous system: a primer for neuroscientists.","authors":"Fumi Suomi, Thomas G McWilliams","doi":"10.1042/NS20180134","DOIUrl":"10.1042/NS20180134","url":null,"abstract":"<p><p>Autophagy refers to the lysosomal degradation of damaged or superfluous components and is essential for metabolic plasticity and tissue integrity. This evolutionarily conserved process is particularly vital to mammalian post-mitotic cells such as neurons, which face unique logistical challenges and must sustain homoeostasis over decades. Defective autophagy has pathophysiological importance, especially for human neurodegeneration. The present-day definition of autophagy broadly encompasses two distinct yet related phenomena: non-selective and selective autophagy. In this minireview, we focus on established and emerging concepts in the field, paying particular attention to the physiological significance of macroautophagy and the burgeoning world of selective autophagy pathways in the context of the vertebrate nervous system. By highlighting established basics and recent breakthroughs, we aim to provide a useful conceptual framework for neuroscientists interested in autophagy, in addition to autophagy enthusiasts with an eye on the nervous system.</p>","PeriodicalId":74287,"journal":{"name":"Neuronal signaling","volume":"3 3","pages":"NS20180134"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37816262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}